Pharma Focus Asia

WuXi Biologics Plans to Invest US$ 382 million to Build Largest Biomanufacturing Facility Centre in Ireland

Introduction:

WuXi Biologics announces to make an investment of US$382 million to construct a largest Biomanufacturing facility centre in Ireland using single-use biologics approach.

Features:

The Biomanufacturing facility centre is proposed to get constructed on the 26-hectare campus of WuXi Biologics in Ireland.

The expansion plan is expected to create nearly 400 highly skilled new jobs over a period of five years in the area of biologics as well as approximately other 700 construction jobs.

This plant is going to be the world’s largest Biomanufacturing facility plant which will significantly utilise single-use bioreactors with an overall installed capacity of 48,000 L fed-batch and 6,000 L perfusion bioreactor.

The new state-of-the-art next-gen biomanufacturing facility will ensure the highest quality manufacturing of biologics with a robust supply chain to benefit patients globally.

The other companies which are going to partner with WuXi Biologics in the construction of Biomanufacturing facility centre are IDA, ISIF, and WuXi AppTec Group.

Specifications:

NameWuXi Biologics
LocationIreland
TypeExpansion
Estimated BudgetUS$ 382 million
Parties InvolvedWuXi Biologics, IDA, ISIS & WuXi AppTech Group
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference